Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1 - PubMed (original) (raw)
. 2004 Mar 11;23(10):1809-20.
doi: 10.1038/sj.onc.1207302.
Affiliations
- PMID: 14647430
- DOI: 10.1038/sj.onc.1207302
Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1
José Antonio Rodriguez et al. Oncogene. 2004.
Abstract
The breast cancer-associated protein, BARD1, colocalizes with BRCA1 in nuclear foci in the S phase and after DNA damage, and the two proteins form a stable heterodimer implicated in DNA repair, protein ubiquitination, and control of mRNA processing. BARD1 has a BRCA1-independent proapoptotic activity; however, little is known about its regulation. Here, we show that BARD1 localization and apoptotic activity are regulated by nuclear-cytoplasmic shuttling. We identified a functional CRM1-dependent nuclear export sequence (NES) near the N-terminal RING domain of BARD1. The NES forms part of the BRCA1 dimerization domain, and coexpression of BRCA1 resulted in masking of the NES and nuclear retention of BARD1. In transient expression assays, BARD1 apoptotic activity was stimulated by nuclear export, and both apoptotic function and nuclear export were markedly reduced by BRCA1. Similar findings were obtained for endogenous BARD1. Silencing BRCA1 expression by siRNA, or disrupting the endogenous BARD1/BRCA1 interaction by peptide competition caused a reduction in BARD1 nuclear localization and foci formation, and increased the level of cytoplasmic BARD1 correlating with increased apoptosis. Our findings suggest that BRCA1/BARD1 heterodimer formation is important for optimal nuclear targeting of BARD1 and its role in DNA repair and cell survival.
Similar articles
- BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.
Fabbro M, Schuechner S, Au WW, Henderson BR. Fabbro M, et al. Exp Cell Res. 2004 Aug 15;298(2):661-73. doi: 10.1016/j.yexcr.2004.05.004. Exp Cell Res. 2004. PMID: 15265711 - Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking.
Henderson BR. Henderson BR. Bioessays. 2005 Sep;27(9):884-93. doi: 10.1002/bies.20277. Bioessays. 2005. PMID: 16108063 Review. - BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export.
Fabbro M, Rodriguez JA, Baer R, Henderson BR. Fabbro M, et al. J Biol Chem. 2002 Jun 14;277(24):21315-24. doi: 10.1074/jbc.M200769200. Epub 2002 Mar 29. J Biol Chem. 2002. PMID: 11925436 - Differential modulation of BRCA1 and BARD1 nuclear localisation and foci assembly by DNA damage.
Brodie KM, Henderson BR. Brodie KM, et al. Cell Signal. 2010 Feb;22(2):291-302. doi: 10.1016/j.cellsig.2009.09.034. Epub 2009 Sep 29. Cell Signal. 2010. PMID: 19796682 - The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.
Baer R, Ludwig T. Baer R, et al. Curr Opin Genet Dev. 2002 Feb;12(1):86-91. doi: 10.1016/s0959-437x(01)00269-6. Curr Opin Genet Dev. 2002. PMID: 11790560 Review.
Cited by
- Nuclear-to-cytoplasmic relocalization of the proliferating cell nuclear antigen (PCNA) during differentiation involves a chromosome region maintenance 1 (CRM1)-dependent export and is a prerequisite for PCNA antiapoptotic activity in mature neutrophils.
Bouayad D, Pederzoli-Ribeil M, Mocek J, Candalh C, Arlet JB, Hermine O, Reuter N, Davezac N, Witko-Sarsat V. Bouayad D, et al. J Biol Chem. 2012 Sep 28;287(40):33812-25. doi: 10.1074/jbc.M112.367839. Epub 2012 Jul 30. J Biol Chem. 2012. PMID: 22846997 Free PMC article. - Biophysical evaluation to categorize pathogenicity of cancer-predisposing mutations identified in the BARD1 BRCT domain.
Choudhary RK, Siddiqui MQ, Gadewal N, Kumar NS, Kuligina ES, Varma AK. Choudhary RK, et al. RSC Adv. 2018 Oct 3;8(59):34056-34068. doi: 10.1039/c8ra06524a. eCollection 2018 Sep 28. RSC Adv. 2018. PMID: 35548793 Free PMC article. - A guide for functional analysis of BRCA1 variants of uncertain significance.
Millot GA, Carvalho MA, Caputo SM, Vreeswijk MP, Brown MA, Webb M, Rouleau E, Neuhausen SL, Hansen Tv, Galli A, Brandão RD, Blok MJ, Velkova A, Couch FJ, Monteiro AN; ENIGMA Consortium Functional Assay Working Group. Millot GA, et al. Hum Mutat. 2012 Nov;33(11):1526-37. doi: 10.1002/humu.22150. Epub 2012 Jul 16. Hum Mutat. 2012. PMID: 22753008 Free PMC article. Review. - The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma.
Sellin M, Berg S, Hagen P, Zhang J. Sellin M, et al. Transl Oncol. 2022 Aug;22:101448. doi: 10.1016/j.tranon.2022.101448. Epub 2022 Jun 1. Transl Oncol. 2022. PMID: 35660848 Free PMC article. Review. - Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, Hinson S, Brinkworth R, Bekessy A, Diez O, Izatt L, Solomon E, Jenkins M, Renard H, Hopper J, Waring P, Tavtigian SV, Goldgar D, Lindeman GJ, Visvader JE, Couch FJ, Henderson BR, Southey M, Chenevix-Trench G, Spurdle AB, Brown MA; kConFab Investigators. Lovelock PK, et al. J Med Genet. 2006 Jan;43(1):74-83. doi: 10.1136/jmg.2005.033258. Epub 2005 May 27. J Med Genet. 2006. PMID: 15923272 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous